Breaking News Instant updates and real-time market news.

ATRA

Atara Biotherapeutics

$16.54 /

-0.53 (-3.10%)

11:00
03/02/21
03/02
11:00
03/02/21
11:00

Atara Biotherapeutics upgraded to Buy from Neutral at Citi

Citi analyst Yigal Nochomovitz upgraded Atara Biotherapeutics to Buy from Neutral with a $27 price target.

  • 27

    May

  • 09

    Dec

ATRA Atara Biotherapeutics
$16.54 /

-0.53 (-3.10%)

01/04/21 Roth Capital
Roth keeps Buy rating on Atara Biotherapeutics after filing delay
01/04/21 Roth Capital
Roth keeps Buy rating on Atara as initiation of BLA gets 'slightly' delayed
12/09/20 Citi
Atara Biotherapeutics downgraded to Neutral from Buy at Citi
12/08/20 H.C. Wainwright
Atara Biotherapeutics price target raised to $31 from $28 at H.C. Wainwright

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 01:50
04/14/21
04/14
01:50
04/14/21
01:50
$ECON

Economic Data

/

+

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
    Downgrade
    Organigram downgraded to Underperformer from Neutral at CIBC » 21:33
    04/13/21
    04/13
    21:33
    04/13/21
    21:33
    OGI

    Organigram

    $2.92 /

    +0.145 (+5.23%)

    CIBC analyst John Zamparo…

    CIBC analyst John Zamparo downgraded Organigram to Underperformer from Neutral with a C$3.25 price target.

    ShowHide Related Items >><<
    OGI Organigram
    $2.92 /

    +0.145 (+5.23%)

    OGI Organigram
    $2.92 /

    +0.145 (+5.23%)

    04/13/21 Alliance Global Partners
    Organigram price target lowered to C$3.75 from C$4 at Alliance Global Partners
    04/07/21 BMO Capital
    Organigram upgraded to Market Perform from Underperform at BMO Capital
    03/16/21 Stifel
    Organigram price target raised to C$6 from C$1.90 at Stifel
    03/15/21 BMO Capital
    Organigram price target raised to C$4 from C$2 at BMO Capital
    OGI Organigram
    $2.92 /

    +0.145 (+5.23%)

    OGI Organigram
    $2.92 /

    +0.145 (+5.23%)

    OGI Organigram
    $2.92 /

    +0.145 (+5.23%)

    OGI Organigram
    $2.92 /

    +0.145 (+5.23%)

    Hot Stocks
    Splunk CEO sells 15.5K shares of common stock » 20:28
    04/13/21
    04/13
    20:28
    04/13/21
    20:28
    SPLK

    Splunk

    $147.69 /

    +3.07 (+2.12%)

    In a regulatory filing,…

    In a regulatory filing, Splunk disclosed that its CEO Douglas Merritt sold 15,465 shares of common stock on April 12th in a total transaction size of $2.24M, reducing his stake by about 5%.

    ShowHide Related Items >><<
    SPLK Splunk
    $147.69 /

    +3.07 (+2.12%)

    SPLK Splunk
    $147.69 /

    +3.07 (+2.12%)

    04/08/21 BofA
    Splunk reinstated with a Buy at BofA
    04/08/21 BofA
    Splunk reinstated with a Buy at BofA
    04/05/21 Goldman Sachs
    Splunk chief growth officer hire a 'significant positive,' says Goldman Sachs
    03/15/21 Credit Suisse
    Splunk assumed with an Outperform at Credit Suisse
    SPLK Splunk
    $147.69 /

    +3.07 (+2.12%)

    SPLK Splunk
    $147.69 /

    +3.07 (+2.12%)

    SPLK Splunk
    $147.69 /

    +3.07 (+2.12%)

    SPLK Splunk
    $147.69 /

    +3.07 (+2.12%)

    Periodicals
    KKR, Brookfield Asset Management mulling bid for Toshiba, Bloomberg reports  20:22
    04/13/21
    04/13
    20:22
    04/13/21
    20:22
    TOSBF

    Toshiba, also use TOSYY

    $44.83 /

    +4.41 (+10.91%)

    , TOSYY

    Toshiba

    $23.28 /

    +2.43 (+11.65%)

    , KKR

    KKR

    $52.04 /

    +0.025 (+0.05%)

    , BAM

    Brookfield

    $45.52 /

    -0.44 (-0.96%)

     
    ShowHide Related Items >><<
    TOSYY Toshiba
    $23.28 /

    +2.43 (+11.65%)

    KKR KKR
    $52.04 /

    +0.025 (+0.05%)

    BAM Brookfield
    $45.52 /

    -0.44 (-0.96%)

    TOSBF Toshiba, also use TOSYY
    $44.83 /

    +4.41 (+10.91%)

    04/22/20 UBS
    Toshiba downgraded to Neutral from Buy at UBS
    TOSYY Toshiba
    $23.28 /

    +2.43 (+11.65%)

    03/19/21 SMBC Nikko
    Toshiba upgraded to Outperform from Neutral at SMBC Nikko
    02/19/21 Citi
    Toshiba resumed with a Neutral at Citi
    KKR KKR
    $52.04 /

    +0.025 (+0.05%)

    04/09/21 DA Davidson
    Box price target lowered to $22 from $25 at DA Davidson
    04/09/21 William Blair
    KKR investment 'strong vote of confidence' in Box, says William Blair
    04/09/21 William Blair
    KKR investment 'strong vote of confidence' in Box, says William Blair
    04/07/21 Seaport Global
    Seaport downgrades Sempra Energy to Neutral after 'good, not great' SIP deal
    BAM Brookfield
    $45.52 /

    -0.44 (-0.96%)

    04/09/21 Deutsche Bank
    Brookfield price target raised to $45 from $43 at Deutsche Bank
    04/01/21 Evercore ISI
    Brookfield Property downgraded to In Line from Outperform at Evercore ISI
    03/31/21
    Fly Intel: Top five analyst downgrades
    03/31/21 Credit Suisse
    Brookfield downgraded to Neutral from Outperform at Credit Suisse
    KKR KKR
    $52.04 /

    +0.025 (+0.05%)

    BAM Brookfield
    $45.52 /

    -0.44 (-0.96%)

    • 11
      Nov
    TOSYY Toshiba
    $23.28 /

    +2.43 (+11.65%)

    TOSBF Toshiba, also use TOSYY
    $44.83 /

    +4.41 (+10.91%)

    KKR KKR
    $52.04 /

    +0.025 (+0.05%)

    BAM Brookfield
    $45.52 /

    -0.44 (-0.96%)

    TOSYY Toshiba
    $23.28 /

    +2.43 (+11.65%)

    KKR KKR
    $52.04 /

    +0.025 (+0.05%)

    BAM Brookfield
    $45.52 /

    -0.44 (-0.96%)

    Earnings
    Steel Partners reports Q4 adjusted EBITDA $67.1M vs. $46.6M last year » 20:12
    04/13/21
    04/13
    20:12
    04/13/21
    20:12
    SPLP

    Steel Partners

    $14.35 /

    + (+0.00%)

    Reports Q4 revenue…

    Reports Q4 revenue $338.7M vs. $346.7M last year. Executive Chairman Warren Lichtenstein: "We were able to respond to the pandemic and economic volatility by reducing costs, improving our operational performance, and increasing our financial flexibility, which led to increased EBITDA and cash flow despite reduced revenue in 2020."

    ShowHide Related Items >><<
    SPLP Steel Partners
    $14.35 /

    + (+0.00%)

    SPLP Steel Partners
    $14.35 /

    + (+0.00%)

    SPLP Steel Partners
    $14.35 /

    + (+0.00%)

    Initiation
    Retail Opportunity reinstated with an Outperform at Baird » 20:06
    04/13/21
    04/13
    20:06
    04/13/21
    20:06
    ROIC

    Retail Opportunity

    $16.49 /

    +0.085 (+0.52%)

    Baird analyst Wesley…

    Baird analyst Wesley Golladay reinstated coverage of Retail Opportunity with an Outperform rating and $18 price target.

    ShowHide Related Items >><<
    ROIC Retail Opportunity
    $16.49 /

    +0.085 (+0.52%)

    ROIC Retail Opportunity
    $16.49 /

    +0.085 (+0.52%)

    02/24/21 DA Davidson
    Retail Opportunity price target raised to $18 from $12 at DA Davidson
    01/19/21 BofA
    Retail Opportunity double-upgraded to Buy from Underperform at BofA
    01/19/21 BofA
    Retail Opportunity upgraded to Buy from Underperform at BofA
    12/14/20 KeyBanc
    Retail Opportunity downgraded to Sector Weight from Overweight at KeyBanc
    ROIC Retail Opportunity
    $16.49 /

    +0.085 (+0.52%)

    Initiation
    RPT Realty reinstated with a Neutral at Baird » 20:06
    04/13/21
    04/13
    20:06
    04/13/21
    20:06
    RPT

    RPT Realty

    $11.83 /

    +0.025 (+0.21%)

    Baird analyst Wesley…

    Baird analyst Wesley Golladay reinstated coverage of RPT Realty with a Neutral rating and $12 price target.

    ShowHide Related Items >><<
    RPT RPT Realty
    $11.83 /

    +0.025 (+0.21%)

    RPT RPT Realty
    $11.83 /

    +0.025 (+0.21%)

    01/13/21 Jefferies
    Jefferies upgrades 'overlooked' RPT Realty to Buy
    01/13/21 Jefferies
    RPT Realty upgraded to Buy from Hold at Jefferies
    12/21/20 JPMorgan
    JPMorgan changes ratings in REIT, Real Estate Services sectors into 2021
    12/21/20 JPMorgan
    RPT Realty upgraded to Neutral from Underweight at JPMorgan
    RPT RPT Realty
    $11.83 /

    +0.025 (+0.21%)

    Initiation
    Retail Properties of America reinstated with a Neutral at Baird » 20:04
    04/13/21
    04/13
    20:04
    04/13/21
    20:04
    RPAI

    Retail Properties of America

    $10.90 /

    -0.005 (-0.05%)

    Baird analyst Wesley…

    Baird analyst Wesley Golladay reinstated coverage of Retail Properties of America with a Neutral rating and $12 price target.

    ShowHide Related Items >><<
    RPAI Retail Properties of America
    $10.90 /

    -0.005 (-0.05%)

    RPAI Retail Properties of America
    $10.90 /

    -0.005 (-0.05%)

    03/04/21
    Fly Intel: Top five analyst downgrades
    03/04/21 KeyBanc
    Retail Properties of America downgraded to Sector Weight at KeyBanc
    03/04/21 KeyBanc
    Retail Properties downgraded to Sector Weight from Overweight at KeyBanc
    12/15/20 Citi
    Retail Properties of America price target raised to $9.50 from $7 at Citi
    RPAI Retail Properties of America
    $10.90 /

    -0.005 (-0.05%)

    Initiation
    Regency Centers reinstated with a Neutral at Baird » 20:04
    04/13/21
    04/13
    20:04
    04/13/21
    20:04
    REG

    Regency Centers

    $59.24 /

    +0.84 (+1.44%)

    Baird analyst Wesley…

    Baird analyst Wesley Golladay reinstated coverage of Regency Centers with a Neutral rating.

    ShowHide Related Items >><<
    REG Regency Centers
    $59.24 /

    +0.84 (+1.44%)

    REG Regency Centers
    $59.24 /

    +0.84 (+1.44%)

    03/31/21 Truist
    Regency Centers price target raised to $57 from $50 at Truist
    03/16/21 Wells Fargo
    Regency Centers price target raised to $63 from $52 at Wells Fargo
    03/04/21 Argus
    Regency Centers downgraded to Hold from Buy at Argus
    03/04/21 Argus
    Regency Centers downgraded to Hold from Buy at Argus
    REG Regency Centers
    $59.24 /

    +0.84 (+1.44%)

    REG Regency Centers
    $59.24 /

    +0.84 (+1.44%)

    Initiation
    Kimco Realty reinstated with an Outperform at Baird » 20:02
    04/13/21
    04/13
    20:02
    04/13/21
    20:02
    KIM

    Kimco Realty

    $19.68 /

    +0.22 (+1.13%)

    Baird analyst Wesley…

    Baird analyst Wesley Golladay reinstated coverage of Kimco Realty with an Outperform rating and $21 price target.

    ShowHide Related Items >><<
    KIM Kimco Realty
    $19.68 /

    +0.22 (+1.13%)

    KIM Kimco Realty
    $19.68 /

    +0.22 (+1.13%)

    03/05/21 Truist
    Kimco Realty price target raised to $20 from $18 at Truist
    02/12/21 Mizuho
    Kimco Realty price target raised to $20 from $17 at Mizuho
    01/11/21 Mizuho
    Kimco Realty upgraded to Buy from Neutral at Mizuho
    KIM Kimco Realty
    $19.68 /

    +0.22 (+1.13%)

    KIM Kimco Realty
    $19.68 /

    +0.22 (+1.13%)

    Initiation
    Weingarten Realty reinstated with an Outperform at Baird » 20:01
    04/13/21
    04/13
    20:01
    04/13/21
    20:01
    WRI

    Weingarten Realty

    $27.49 /

    +0.38 (+1.40%)

    Baird analyst Wesley…

    Baird analyst Wesley Golladay reinstated coverage of Weingarten Realty with an Outperform rating and $29 price target.

    ShowHide Related Items >><<
    WRI Weingarten Realty
    $27.49 /

    +0.38 (+1.40%)

    WRI Weingarten Realty
    $27.49 /

    +0.38 (+1.40%)

    03/09/21 BTIG
    Weingarten Realty price target raised to $28 from $25 at BTIG
    03/05/21 Truist
    Weingarten Realty price target raised to $28 from $24 at Truist
    01/28/21 Scotiabank
    Weingarten Realty upgraded to Outperform at Scotiabank on 'Sunbelt preference'
    01/28/21 Scotiabank
    Weingarten Realty upgraded to Outperform from Sector Perform at Scotiabank
    WRI Weingarten Realty
    $27.49 /

    +0.38 (+1.40%)

    Downgrade
    FLSmidth double-downgraded to Sell from Buy at Goldman Sachs » 19:59
    04/13/21
    04/13
    19:59
    04/13/21
    19:59
    FLIDY

    FLSmidth

    $3.74 /

    -0.11 (-2.86%)

    Goldman Sachs analyst…

    Goldman Sachs analyst Hameed Awan downgraded FLSmidth to Sell from Buy with a DKK 208 price target. The analyst says he is broadly positive on underlying trends in mining equipment, but FLSmidth's exposure to late-cycle spending means it will see a cyclical upswing later than some industry peers. Awan adds that he sees continued structural challenges in Cement given significant overcapacity and pricing pressure.

    ShowHide Related Items >><<
    FLIDY FLSmidth
    $3.74 /

    -0.11 (-2.86%)

    02/19/21 RBC Capital
    FLSmidth price target lowered to DKK 255 from DKK 270 at RBC Capital
    02/11/21 Morgan Stanley
    FLSmidth price target lowered to DKK 190 from DKK 200 at Morgan Stanley
    12/08/20 Nordea
    FLSmidth upgraded to Buy from Hold at Nordea
    12/07/20 JPMorgan
    FLSmidth price target raised to DKK 245 from DKK 230 at JPMorgan
    Initiation
    Epiroc initiated with a Buy at Goldman Sachs » 19:55
    04/13/21
    04/13
    19:55
    04/13/21
    19:55
    EPOKY

    Epiroc

    $23.87 /

    +0.06 (+0.25%)

    Goldman Sachs analyst…

    Goldman Sachs analyst Hameed Awan initiated coverage of Epiroc with a Buy rating and SEK 235 price target. The analyst is positive on the company's position as a premium player in the most attractive segment of the mining equipment market, along with its early cycle positioning with exposure to upstream and early-cycle mining equipment spending. Awan further cites the longer term industry shift towards underground mining where Epiroc holds strong share with a long track record.

    ShowHide Related Items >><<
    EPOKY Epiroc
    $23.87 /

    +0.06 (+0.25%)

    EPOKY Epiroc
    $23.87 /

    +0.06 (+0.25%)

    04/13/21 UBS
    Epiroc price target raised to SEK 200 from SEK 159 at UBS
    04/13/21 Pareto
    Epiroc downgraded to Sell from Hold at Pareto
    04/12/21 Societe Generale
    Epiroc downgraded to Hold on valuation at Societe Generale
    04/12/21 Societe Generale
    Epiroc downgraded to Hold from Buy at Societe Generale
    Initiation
    Metso Outotec reinstated with a Neutral at Goldman Sachs » 19:53
    04/13/21
    04/13
    19:53
    04/13/21
    19:53
    OUKPY

    Metso Outotec

    $5.66 /

    +0.04 (+0.71%)

    Goldman Sachs analyst…

    Goldman Sachs analyst Hameed Awan reinstated coverage of Metso Outotec with a Neutral rating and EUR 9.8 price target. The company's mid-term growth and returns trajectory is reflected in the current shares, even though the combined entity has executed strongly on its EUR120M cost synergies target following the merger of Metso and Outotec merger in June 2020, the analyst tells investors in a research note.

    ShowHide Related Items >><<
    OUKPY Metso Outotec
    $5.66 /

    +0.04 (+0.71%)

    04/12/21 Societe Generale
    Metso Outotec price target raised to EUR 11 from EUR 8.40 at Societe Generale
    02/19/21 Credit Suisse
    Metso Outotec price target raised to EUR 10.50 from EUR 9.40 at Credit Suisse
    02/17/21 UBS
    Metso Outotec price target raised to EUR 10.4 from EUR 10 at UBS
    02/17/21 Morgan Stanley
    Metso Outotec price target raised to EUR 9.60 from EUR 9.30 at Morgan Stanley
    Upgrade
    JFrog upgraded to Hold from Sell at Summit Insights » 19:06
    04/13/21
    04/13
    19:06
    04/13/21
    19:06
    FROG

    JFrog

    $51.99 /

    +0.68 (+1.33%)

    Summit Insights analyst…

    Summit Insights analyst Srini Nandury upgraded JFrog to Hold from Sell with a $50 price target.

    ShowHide Related Items >><<
    FROG JFrog
    $51.99 /

    +0.68 (+1.33%)

    FROG JFrog
    $51.99 /

    +0.68 (+1.33%)

    01/05/21 Piper Sandler
    JFrog price target lowered to $65 from $76 at Piper Sandler
    11/05/20 Stifel
    JFrog reported 'strong first print as a public company,' says Stifel
    10/26/20 Stifel
    SAP news impact may be company-specific for software sector, says Stifel
    10/12/20 JPMorgan
    JFrog initiated with an Overweight at JPMorgan
    FROG JFrog
    $51.99 /

    +0.68 (+1.33%)

    • 16
      Sep
    FROG JFrog
    $51.99 /

    +0.68 (+1.33%)

    FROG JFrog
    $51.99 /

    +0.68 (+1.33%)

    FROG JFrog
    $51.99 /

    +0.68 (+1.33%)

    Hot Stocks
    Galectin says Phase 1 belapectin data published in JITC » 19:03
    04/13/21
    04/13
    19:03
    04/13/21
    19:03
    GALT

    Galectin Therapeutics

    $2.17 /

    -0.105 (-4.62%)

    Galectin Therapeutics…

    Galectin Therapeutics announced that a paper published in the peer-reviewed Journal for ImmunoTherapy of Cancer, the highest ranked fully open access immunology journal, provides further clinical evidence that using belapectin, a potent galectin-3 inhibitor, in combination with pembrolizumab, a PD-1 inhibitor, significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma and head and neck squamous cell carcinoma. The paper, titled "Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor" describes results from an ongoing Phase 1 clinical study, a collaboration between Galectin Therapeutics and Providence Cancer Institute in Portland, Oregon. Following the recent publication of positive preclinical results that showed the inhibition of galectin-3 in combination with an agonist anti-OX40 monoclonal antibody reprograms the tumor microenvironment to favor anti-tumor activity, the current study tests the clinical hypothesis that galectin-3 blockade with belapectin in combination with pembrolizumab enhances tumor response for patients with advanced MM or HNSCC. In the study, as previously disclosed, an objective response was observed in 50% of MM and 33% of HNSCC patients. This compares favorably to published response rates on pembrolizumab alone. The authors noted that the combination was associated with fewer immune-mediated adverse events than anticipated with pembrolizumab alone. In addition, the analysis of patients' tumor tissue revealed reduced monocytic myeloid-derived suppressor cells and increased effector memory T-cell activation in responders compared with non-responders. Also, an increased baseline expression of galectin-3 positive tumor cells correlated with clinical response.

    ShowHide Related Items >><<
    GALT Galectin Therapeutics
    $2.17 /

    -0.105 (-4.62%)

    GALT Galectin Therapeutics
    $2.17 /

    -0.105 (-4.62%)

    Earnings
    Washington Federal reports Q2 EPS 56c, consensus 48c » 19:02
    04/13/21
    04/13
    19:02
    04/13/21
    19:02
    WAFD

    Washington Federal

    $30.81 /

    -0.64 (-2.03%)

    Reports Q2 NII $124.0M…

    Reports Q2 NII $124.0M vs. $109.4M last year and net interest margin 2.75% vs. 3.10% last year.

    ShowHide Related Items >><<
    WAFD Washington Federal
    $30.81 /

    -0.64 (-2.03%)

    WAFD Washington Federal
    $30.81 /

    -0.64 (-2.03%)

    WAFD Washington Federal
    $30.81 /

    -0.64 (-2.03%)

    Hot Stocks
    J&J pauses vaccinations in all COVID-19 vaccine clinical trials » 18:54
    04/13/21
    04/13
    18:54
    04/13/21
    18:54
    JNJ

    Johnson & Johnson

    $159.51 /

    -2.075 (-1.28%)

    In an updated statement,…

    In an updated statement, Johnson & Johnson said that it has made the decision to proactively delay the rollout of its COVID-19 vaccine in Europe and pause vaccinations in all Janssen COVID-19 vaccine clinical trials while it updates guidance for investigators and participants. "We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public," the company said. Reference Link

    ShowHide Related Items >><<
    JNJ Johnson & Johnson
    $159.51 /

    -2.075 (-1.28%)

    JNJ Johnson & Johnson
    $159.51 /

    -2.075 (-1.28%)

    04/13/21 Goldman Sachs
    J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
    04/13/21 Morgan Stanley
    Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
    04/13/21 JPMorgan
    Vaccine pause 'incremental negative' for J&J, says JPMorgan
    04/13/21 Piper Sandler
    Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
    JNJ Johnson & Johnson
    $159.51 /

    -2.075 (-1.28%)

    JNJ Johnson & Johnson
    $159.51 /

    -2.075 (-1.28%)

    JNJ Johnson & Johnson
    $159.51 /

    -2.075 (-1.28%)

    JNJ Johnson & Johnson
    $159.51 /

    -2.075 (-1.28%)

    Hot Stocks
    Televisa, Univision agree to combine content, production assets » 18:40
    04/13/21
    04/13
    18:40
    04/13/21
    18:40
    TV

    Televisa

    $10.12 /

    +0.09 (+0.90%)

    , SFTBY

    SoftBank

    $46.60 /

    +0.155 (+0.33%)

    Televisa (TV) and…

    Televisa (TV) and Univision announced that they have finalized a deal to combine their content and production assets. Televisa will receive $3B in cash and $1.5B in equity as part of the deal, and SoftBank (SFTBY) will invest $1B in the combined entity. Reference Link

    ShowHide Related Items >><<
    SFTBY SoftBank
    $46.60 /

    +0.155 (+0.33%)

    TV Televisa
    $10.12 /

    +0.09 (+0.90%)

    03/17/21 BBVA
    Televisa upgraded to Outperform from Market Perform at BBVA
    12/15/20 Morgan Stanley
    Televisa downgraded to Equal Weight following rally at Morgan Stanley
    12/15/20 Morgan Stanley
    Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
    05/12/20 Credit Suisse
    Televisa upgraded to Outperform from Neutral at Credit Suisse
    SFTBY SoftBank
    $46.60 /

    +0.155 (+0.33%)

    03/11/21 Jefferies
    SoftBank downgraded to Hold from Buy at Jefferies
    03/10/21 Morgan Stanley
    SoftBank resumed with an Equal Weight at Morgan Stanley
    11/27/20 Citi
    SoftBank price target raised to 11,000 yen from 10,200 yen at Citi
    09/18/20 Northland
    Combined Nvidia-ARM a long-term risk for AMD, Intel and Vicor, says Northland
    TV Televisa
    $10.12 /

    +0.09 (+0.90%)

    SFTBY SoftBank
    $46.60 /

    +0.155 (+0.33%)

    SFTBY SoftBank
    $46.60 /

    +0.155 (+0.33%)

    Periodicals
    Televisa to combine content, production assets with Univision, Bloomberg says » 18:37
    04/13/21
    04/13
    18:37
    04/13/21
    18:37
    TV

    Televisa

    $10.12 /

    +0.09 (+0.90%)

    Televisa will receive $3B…

    Televisa will receive $3B in cash and $1.5B in equity as part of the deal, according to Bloomberg.

    ShowHide Related Items >><<
    TV Televisa
    $10.12 /

    +0.09 (+0.90%)

    03/17/21 BBVA
    Televisa upgraded to Outperform from Market Perform at BBVA
    12/15/20 Morgan Stanley
    Televisa downgraded to Equal Weight following rally at Morgan Stanley
    12/15/20 Morgan Stanley
    Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
    05/12/20 Credit Suisse
    Televisa upgraded to Outperform from Neutral at Credit Suisse
    Upgrade
    Glencore upgraded to Buy from Neutral at Goldman Sachs » 18:35
    04/13/21
    04/13
    18:35
    04/13/21
    18:35
    GLNCY

    Glencore

    $7.85 /

    +0.03 (+0.38%)

    Goldman Sachs analyst…

    Goldman Sachs analyst Jack O'Brien upgraded Glencore to Buy from Neutral with a price target of 350 GBp, up from 290 GBp. The company is the biggest beneficiary of copper's path to $15,000 per ton among industrial miners, the analyst tells investors in a research note, stating that Glencore is the 2nd largest producer of copper globally. O'Brien adds that Glencore's commodity basket, including copper, zinc, nickel, cobalt, is "best placed" vs. peers with regard to the transition to renewables.

    ShowHide Related Items >><<
    GLNCY Glencore
    $7.85 /

    +0.03 (+0.38%)

    GLNCY Glencore
    $7.85 /

    +0.03 (+0.38%)

    04/12/21 Deutsche Bank
    Glencore price target raised to 400 GBp from 350 GBp at Deutsche Bank
    03/24/21 Morgan Stanley
    Glencore price target raised to 307 GBp from 274 GBp at Morgan Stanley
    03/05/21 JPMorgan
    Glencore price target raised to 360 GBp from 350 GBp at JPMorgan
    03/04/21 UBS
    Glencore price target raised to 330 GBp from 320 GBp at UBS
    GLNCY Glencore
    $7.85 /

    +0.03 (+0.38%)

    Periodicals
    Judge says Juul must face new racketeering allegations, Bloomberg says » 18:24
    04/13/21
    04/13
    18:24
    04/13/21
    18:24
    MO

    Altria Group

    $51.16 /

    -0.59 (-1.14%)

    Juul Labs, which is 35%…

    Juul Labs, which is 35% owned by Altria, will have to face new racketeering claims accusing the vaping company of deliberately targeting teenagers, as litigation centers on the individual founders and directors of the company, Bloomberg's Joel Rosenblatt reports. A federal judge in San Francisco said that most of the allegations brought by consumers, local governments, and school district against Juul and Altria under the Racketeer Influenced and Corrupt Organizations Act can proceed, the author notes. Reference Link

    ShowHide Related Items >><<
    MO Altria Group
    $51.16 /

    -0.59 (-1.14%)

    MO Altria Group
    $51.16 /

    -0.59 (-1.14%)

    03/26/21
    Fly Intel: Top five analyst upgrades
    03/26/21 Jefferies
    Altria Group upgraded to Buy from Hold at Jefferies
    03/19/21 Deutsche Bank
    Altria Group price target raised to $54 from $52 at Deutsche Bank
    03/16/21
    Fly Intel: Top five analyst downgrades
    MO Altria Group
    $51.16 /

    -0.59 (-1.14%)

    MO Altria Group
    $51.16 /

    -0.59 (-1.14%)

    MO Altria Group
    $51.16 /

    -0.59 (-1.14%)

    MO Altria Group
    $51.16 /

    -0.59 (-1.14%)

    Hot Stocks
    New Gold reports Q1 gold equivalent production 96,026 ounces » 18:21
    04/13/21
    04/13
    18:21
    04/13/21
    18:21
    NGD

    New Gold

    $1.82 /

    + (+0.00%)

    Reports Q1 gold…

    Reports Q1 gold production 66,650 ounces. Reports Q1 copper production 13.8 Mlbs. "During the quarter, the Rainy River Mine delivered to plan. Waste stripping was strategically prioritized during the winter months, which will set the mine up for higher grades and a stronger production profile in the second half of the year. The New Afton Mine continues to safely and sequentially ramp-up operations and we look forward to initiating ore extraction from the B3 zone. I am very proud of the progress the team has made at New Afton, and coupled with the execution at Rainy River, we remain on-track to achieve our annual guidance estimates," stated Renaud Adams, President & CEO. "Late last year, we re-launched exploration drilling programs at both operations after an extended period of inactivity. We are encouraged by the early-stage results to date."

    ShowHide Related Items >><<
    NGD New Gold
    $1.82 /

    + (+0.00%)

    NGD New Gold
    $1.82 /

    + (+0.00%)

    02/22/21 Canaccord
    New Gold price target lowered to C$2.75 from C$3.75 at Canaccord
    02/11/21 National Bank
    New Gold price target lowered to C$4 from C$4.25 at National Bank
    02/03/21 CIBC
    New Gold downgraded to Neutral after mine fatality at CIBC
    02/02/21 CIBC
    New Gold downgraded to Neutral from Outperformer at CIBC
    NGD New Gold
    $1.82 /

    + (+0.00%)

    On The Fly
    Fly Intel: After-Hours Movers » 18:19
    04/13/21
    04/13
    18:19
    04/13/21
    18:19
    SAP

    SAP

    $134.51 /

    +2.08 (+1.57%)

    , FLXN

    Flexion

    $9.37 /

    +1.05 (+12.62%)

    , BRKR

    Bruker

    $68.97 /

    +1.43 (+2.12%)

    , TEAM

    Atlassian

    $242.24 /

    +11.72 (+5.08%)

    , PKI

    PerkinElmer

    $135.39 /

    +2.695 (+2.03%)

    , MRNA

    Moderna

    $149.63 /

    +10.34 (+7.42%)

    , SEAC

    SeaChange

    $1.38 /

    -0.095 (-6.46%)

    , SFIX

    Stitch Fix

    $49.46 /

    -1.3 (-2.56%)

    , STSA

    Satsuma Pharmaceuticals

    $5.44 /

    +0.37 (+7.30%)

    Check out this evening's…

    ShowHide Related Items >><<
    TEAM Atlassian
    $242.24 /

    +11.72 (+5.08%)

    STSA Satsuma Pharmaceuticals
    $5.44 /

    +0.37 (+7.30%)

    SFIX Stitch Fix
    $49.46 /

    -1.3 (-2.56%)

    SEAC SeaChange
    $1.38 /

    -0.095 (-6.46%)

    SAP SAP
    $134.51 /

    +2.08 (+1.57%)

    PKI PerkinElmer
    $135.39 /

    +2.695 (+2.03%)

    MRNA Moderna
    $149.63 /

    +10.34 (+7.42%)

    FLXN Flexion
    $9.37 /

    +1.05 (+12.62%)

    BRKR Bruker
    $68.97 /

    +1.43 (+2.12%)

    SAP SAP
    $134.51 /

    +2.08 (+1.57%)

    04/09/21 Societe Generale
    SAP price target lowered to EUR 136 from EUR 138 at Societe Generale
    03/25/21 Credit Suisse
    SAP assumed with an Outperform at Credit Suisse
    03/12/21 JMP Securities
    Domo price target raised to $89 from $80 at JMP Securities
    03/10/21 Craig-Hallum
    Talend go-shop 'could spark interest,' says Craig-Hallum
    FLXN Flexion
    $9.37 /

    +1.05 (+12.62%)

    04/06/21 RBC Capital
    Flexion transferred with an Outperform at RBC Capital
    08/20/20 Goldman Sachs
    Flexion initiated with a Neutral at Goldman Sachs
    07/30/20 Oppenheimer
    Flexion initiated with an Outperform at Oppenheimer
    07/29/20
    Fly Intel: Top five analyst initiations
    BRKR Bruker
    $68.97 /

    +1.43 (+2.12%)

    02/17/21 Stifel
    Bruker price target raised to $65 from $48 at Stifel
    02/17/21 Citi
    Bruker price target raised to $65 from $57 at Citi
    02/05/21 Wells Fargo
    Bruker downgraded to Equal Weight with $55 target at Wells Fargo
    02/05/21 Wells Fargo
    Bruker downgraded to Equal Weight from Overweight at Wells Fargo
    TEAM Atlassian
    $242.24 /

    +11.72 (+5.08%)

    03/08/21 Morgan Stanley
    Software industry rating raised to Attractive from In-Line at Morgan Stanley
    03/03/21 Citi
    Atlassian assumed with a Buy at Citi
    01/29/21 DA Davidson
    Atlassian price target raised to $275 from $235 at DA Davidson
    01/29/21 BMO Capital
    Atlassian price target raised to $260 from $235 at BMO Capital
    PKI PerkinElmer
    $135.39 /

    +2.695 (+2.03%)

    02/03/21 Citi
    PerkinElmer price target raised to $155 from $150 at Citi
    01/07/21 Piper Sandler
    Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
    01/07/21 Wells Fargo
    PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
    01/07/21 Wells Fargo
    PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
    MRNA Moderna
    $149.63 /

    +10.34 (+7.42%)

    04/13/21 Morgan Stanley
    Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
    04/13/21 Piper Sandler
    Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
    04/07/21 Jefferies
    Catalent pact with Moderna removes potential overhang, says Jefferies
    03/15/21 Piper Sandler
    Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
    SEAC SeaChange
    $1.38 /

    -0.095 (-6.46%)

    09/09/20 Lake Street
    SeaChange price target lowered to $2 from $4 at Lake Street
    SFIX Stitch Fix
    $49.46 /

    -1.3 (-2.56%)

    04/05/21 Evercore ISI
    Stitch Fix initiated with an Outperform at Evercore ISI
    03/09/21
    Fly Intel: Top five analyst downgrades
    03/09/21 Canaccord
    Stitch Fix price target lowered to $68 from $72 at Canaccord
    03/09/21 KeyBanc
    Stitch Fix price target lowered to $75 from $95 at KeyBanc
    STSA Satsuma Pharmaceuticals
    $5.44 /

    +0.37 (+7.30%)

    04/05/21 Mizuho
    Satsuma Pharmaceuticals price target raised to $7 from $3.50 at Mizuho
    03/02/21 Credit Suisse
    Satsuma Pharmaceuticals upgraded to Neutral from Underperform at Credit Suisse
    03/02/21 Credit Suisse
    Satsuma upgraded to Neutral from Underperform at Credit Suisse
    11/11/20 Mizuho
    Satsuma Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
    TEAM Atlassian
    $242.24 /

    +11.72 (+5.08%)

    STSA Satsuma Pharmaceuticals
    $5.44 /

    +0.37 (+7.30%)

    SFIX Stitch Fix
    $49.46 /

    -1.3 (-2.56%)

    SEAC SeaChange
    $1.38 /

    -0.095 (-6.46%)

    SAP SAP
    $134.51 /

    +2.08 (+1.57%)

    PKI PerkinElmer
    $135.39 /

    +2.695 (+2.03%)

    MRNA Moderna
    $149.63 /

    +10.34 (+7.42%)

    FLXN Flexion
    $9.37 /

    +1.05 (+12.62%)

    BRKR Bruker
    $68.97 /

    +1.43 (+2.12%)

    • 30
      Mar
    • 21
      Oct
    • 21
      May
    • 19
      May
    SAP SAP
    $134.51 /

    +2.08 (+1.57%)

    MRNA Moderna
    $149.63 /

    +10.34 (+7.42%)

    TEAM Atlassian
    $242.24 /

    +11.72 (+5.08%)

    SFIX Stitch Fix
    $49.46 /

    -1.3 (-2.56%)

    SEAC SeaChange
    $1.38 /

    -0.095 (-6.46%)

    SAP SAP
    $134.51 /

    +2.08 (+1.57%)

    PKI PerkinElmer
    $135.39 /

    +2.695 (+2.03%)

    MRNA Moderna
    $149.63 /

    +10.34 (+7.42%)

    BRKR Bruker
    $68.97 /

    +1.43 (+2.12%)

    TEAM Atlassian
    $242.24 /

    +11.72 (+5.08%)

    STSA Satsuma Pharmaceuticals
    $5.44 /

    +0.37 (+7.30%)

    SFIX Stitch Fix
    $49.46 /

    -1.3 (-2.56%)

    SEAC SeaChange
    $1.38 /

    -0.095 (-6.46%)

    SAP SAP
    $134.51 /

    +2.08 (+1.57%)

    MRNA Moderna
    $149.63 /

    +10.34 (+7.42%)

    Upgrade
    South32 upgraded to Conviction Buy from Buy at Goldman Sachs » 17:57
    04/13/21
    04/13
    17:57
    04/13/21
    17:57
    SOUHY

    South32

    $10.96 /

    -0.07 (-0.63%)

    Goldman Sachs analyst…

    Goldman Sachs analyst Paul Young upgraded South32 to Conviction Buy from Buy with a price target of A$3.4, up from A$3.2. The analyst is citing the recent rise in commodity prices, particularly higher aluminium and manganese. Young adds that he is positive on South32's commodity mix, including alumina, met coal and manganese, which represent over 50% of its EBITDA.

    ShowHide Related Items >><<
    SOUHY South32
    $10.96 /

    -0.07 (-0.63%)

    SOUHY South32
    $10.96 /

    -0.07 (-0.63%)

    04/07/21 Barclays
    South32 price target raised to 145 GBp from 130 GBp at Barclays
    03/10/21 Deutsche Bank
    South32 price target lowered to 190 GBp from 200 GBp at Deutsche Bank
    02/08/21 Barclays
    South32 price target raised to 130 GBp from 125 GBp at Barclays
    11/24/20 Barclays
    South32 downgraded to Underweight from Overweight at Barclays

    Get Full Fly Access

    Breaking market intelligence sent straight to you
    Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
    Up-to-date information on important industry events
    Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
    News focused on the companies in your portfolio
    Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.